Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy

Metformin is an oral biguanide commonly used for the treatment of type II diabetes and has recently been demonstrated to possess antiproliferative properties that can be exploited for the prevention and treatment of a variety of cancers. The mechanisms underlying this effect have not been fully eluc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2013-12, Vol.12 (12), p.2847-2856
Hauptverfasser:	Iglesias, David A, Yates, Melinda S, van der Hoeven, Dharini, Rodkey, Travis L, Zhang, Qian, Co, Ngai Na, Burzawa, Jennifer, Chigurupati, Sravanthi, Celestino, Joseph, Bowser, Jessica, Broaddus, Russell, Hancock, John F, Schmandt, Rosemarie, Lu, Karen H
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacology Apoptosis - drug effects Apoptosis - genetics Cell Line, Tumor Cell Proliferation - drug effects Endometrial Neoplasms - genetics Endometrial Neoplasms - metabolism Endometrial Neoplasms - pathology Female Gene Silencing Humans Metformin - pharmacology Mice Mutation Protein Kinase C - metabolism Protein Transport Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins p21(ras) PTEN Phosphohydrolase - genetics PTEN Phosphohydrolase - metabolism ras Proteins - genetics ras Proteins - metabolism Signal Transduction - drug effects Tumor Burden - drug effects Tumor Burden - genetics Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!